Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, based in Mumbai, India, operates as a global pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company offers both branded and generic formulations, focusing on therapeutic areas such as dermatology, respiratory, and oncology. Glenmark's product pipeline is robust, featuring candidates like ISB 830 for atopic dermatitis and ISB 1302 for metastatic HER2-positive breast cancer, among others. The company also produces various active pharmaceutical ingredients and has a pre-clinical pipeline targeting conditions such as chronic obstructive pulmonary disorder and various cancers. Founded in 1977, Glenmark has established itself as a leader in research and development, emphasizing the discovery of new chemical and biological entities to address unmet medical needs across diverse therapeutic categories, including diabetes and cardiovascular health.